

BIOCON BIOLOGICS FINLAND OY
BALANCE SHEET AS AT MARCH 31, 2026

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31, 2026</u>	<u>March 31, 2025</u>
ASSETS			
Current assets			
Financial assets			
(i) Trade receivables	1	613	452
(ii) Cash and cash equivalents	2	43	233
Other current assets	3	62	43
Total current assets		718	728
TOTAL		718	728
EQUITY AND LIABILITIES			
Equity			
Equity share capital	4	-	-
Other equity	5	80	46
Total equity		80	46
Current liabilities			
Financial liabilities			
(i) Trade payables	6	615	589
(ii) Other financial liabilities			
Income-tax liability (net)		12	12
Provisions	7	-	73
Other liabilities	8	11	8
Total current liabilities		638	682
TOTAL		718	728

BIOCON BIOLOGICS FINLAND OY**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	Year ended March 31, 2026	Year ended March 31, 2025
Income			
Revenue from operations	9	925	961
Other operating income	10	(22)	12
Total revenue		903	973
Expenses			
Purchases of traded goods	11	-	(32)
Employee benefits expense	12	425	536
Other expenses	13	434	423
Total expenses		859	927
Profit before tax		44	46
Tax expense			
Current tax		10	3
Deferred Tax		-	6
Total tax expense		10	9
Profit for the year		34	36

BIOCON BIOLOGICS FINLAND OY**STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
I Cash flows from operating activities		
Profit after tax	34	37
<u>Adjustments to reconcile profit before tax to net cash flows:</u>		
Unrealised foreign exchange (gain)/loss	(22)	12
Tax expense	10	9
Operating profit before working capital changes	22	58
Movements in working capital		
(Increase) in trade receivables	(161)	(233)
(Increase) in loans and advances and other assets	(19)	(39)
(Decrease)/Increase in trade payable, other liabilities and provisions	(44)	389
Cash (used in)/generated from operations	(202)	175
Direct taxes paid	(10)	-
Net cash flow (used in)/generated from operating activities	(212)	175
II Net (increase)/decrease in cash and cash equivalents	(212)	175
III Effect of exchange differences on cash and cash equivalents held in foreign currency	22	(12)
IV Cash and cash equivalents at the beginning of the year	233	70
V Cash and cash equivalents at the end of the year (II + III + IV)	43	233
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents		
Balances with banks - on current accounts	43	233
Cash on hand	-	-
	43	233
Total cash and cash equivalents [Refer note 2]	43	233

BIOCON BIOLOGICS FINLAND OY**NOTES TO FINANCIAL STATEMENT FOR THE YEAR ENDED MARCH 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	March 31, 2026	March 31, 2025
1. Trade receivables		
Other Receivables		
Outstanding for a period less than six months from the date they are due for payment		
Unsecured, considered good	613	452
	613	452
2. Cash and cash equivalents		
Balances with banks:		
On current accounts	43	233
	43	233
3. Other current assets		
Prepayments	21	6
Balance with Government Authorities	41	37
	62	43
4. Share capital		
Authorised		
Issued, subscribed and fully paid-up		
Equity share 1 Common stock of EUR 0 each	-	-
	-	-
5. Other equity		
Surplus/(deficit) in the statement of profit and loss		
Balance as per the last financial statements	46	9
Profit for the year	34	37
Net surplus in the statement of profit and loss	80	46
6. Trade payables	615	589
7. Provisions		
Current		
Compensated absences	-	69
	-	69
8. Other liabilities		
Current liabilities		
Statutory liabilities	11	8
	11	8

BIOCON BIOLOGICS FINLAND OY**NOTES TO FINANCIAL STATEMENT FOR THE YEAR ENDED MARCH 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
9. Revenue from operations		
Sale of Services		
Support service cross charge to Group Companies	925	961
	925	961
10. Other operating income		
Foreign exchange fluctuations, net	(22)	12
	(22)	12
11. Purchase of traded goods	-	(32)
	-	(32)
12. Employee benefits expense		
Salaries, wages and bonus	415	521
Staff welfare expenses	10	15
	425	536
13. Other expenses		
Rates and taxes	10	26
Rent	4	2
Legal and professional fees	92	139
Repair and Maintenance	-	20
Research and development expenses	1	1
Travelling and conveyance	6	86
Sales promotion expenses	49	86
Printing and stationery	3	10
Insurance Charges	235	-
Communication expenses	-	2
Miscellaneous expenses	34	51
	434	423